High quality products to support Pathologists and Biological and Environmental Scientists
GeneAb™ p57 kip2
$115.00 – $860.00p57Kip2, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57Kip2 gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms’ tumour, and Beckwith Wiedemann syndrome. Anti-p57Kip2 labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
GeneAb™ CD56
$50.00 – $160.00Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm’s tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
GeneAb™ ROS1
$190.00 – $855.00ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumours have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have observed ROS1 gene rearragement events in approximately 1% of lung cancers and showed that inhibition of tumour cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.
GeneAb™ CD34
$66.00 – $385.00Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
GeneAb™ CD31
$75.00 – $305.00Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
GeneAb™ p27
$100.00 – $370.00p27, also known as p27Kip1, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal cell carcinoma, colon carcinoma, small breast carcinomas, non-small cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
GeneAb™ p16 INK4A
$135.00 – $545.00The p16 (p16INK4A) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
GeneAb™ CD13
$190.00 – $855.00Cluster of Differentiation 13 (CD13) is a transmembrane protein that is overexpressed in both hematological and solid malignancies, including Acute Myeloid Leukemia (AML). Although hypogranular variants of AML are difficult to distinguish from other AML subtypes due to the morphology, the diagnosis of this variant is possible through using a panel of CD13, CD16, CD33, CD34, and CD117. Alternatively, a panel of CD13, CD34, CD43, CD68, CD117, CD163, lysozyme, and MPO is very useful for accurately diagnosing myeloid sarcoma and distinguishing it from large cell lymphoma, undifferentiated carcinoma, lymphoblastic lymphoma, malignant melanoma, Burkitt’s lymphoma, extra-medullary hematopoiesis, and inflammation. Since CD13 is expressed in both normal and neoplastic liver tissues, CD13 staining is useful for distinguishing between hepatocellular carcinoma and non-hepatocellular neoplasms.